Advertisement
CorrigendumImmunology Free access | 10.1172/JCI41250C1
Find articles by Nair-Gill, E. in: JCI | PubMed | Google Scholar
Find articles by Wiltzius, S. in: JCI | PubMed | Google Scholar
Find articles by Wei, X. in: JCI | PubMed | Google Scholar
Find articles by Cheng, D. in: JCI | PubMed | Google Scholar
Find articles by Riedinger, M. in: JCI | PubMed | Google Scholar
Find articles by Radu, C. in: JCI | PubMed | Google Scholar
Find articles by Witte, O. in: JCI | PubMed | Google Scholar
Published July 1, 2010 - More info
Clinical tools that measure changes in immune cell metabolism would improve the diagnosis and treatment of immune dysfunction. PET, utilizing probes for specific metabolic processes, detects regions of immune activation in vivo. In this study we investigated the immune cell specificity of PET probes for two different metabolic pathways: [18F]–2-fluorodeoxyglucose ([18F]-FDG) for glycolysis and [18F]–2-fluoro-d-(arabinofuranosyl)cytosine ([18F]-FAC) for deoxycytidine salvage. We isolated innate and adaptive immune cells from tissues of mice challenged with a retrovirus-induced sarcoma and measured their ability to accumulate FDG and FAC. We determined that the two probes had distinct patterns of accumulation: FDG accumulated to the highest levels in innate immune cells, while FAC accumulated predominantly in CD8+ T cells in a manner that correlated with cellular proliferation. This study demonstrates that innate and adaptive cell types differ in glycolytic and deoxycytidine salvage demands during an immune response and that these differential metabolic requirements can be detected with specific PET probes. Our findings have implications for the interpretation of clinical PET scans that use [18F]-FDG or [18F]-FAC to assess immune function in vivo and suggest potential applications of metabolic PET to monitor the effects of targeted immune modulation.
Evan Nair-Gill, Stephanie M. Wiltzius, Xiao X. Wei, Donghui Cheng, Mireille Riedinger, Caius G. Radu, Owen N. Witte
Original citation: J Clin Invest. 2010;120(6):2005–2015. doi:10.1172/JCI41250.
Citation for this corrigendum: J Clin Invest. 2010;120(7):2641. doi:10.1172/JCI41250C1.
A sentence citing a funding source was inadvertently omitted from the Acknowledgments. The sentence appears below.
This manuscript was also supported by funds from the California Institute for Regenerative Medicine (CIRM) (RT1-01126) Tools and Technology Award.